Document Detail


Use of benzodiazepines or benzodiazepine related drugs and the risk of cancer: a population-based case-control study.
MedLine Citation:
PMID:  23043261     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIM: Studies of the carcinogenic potential of benzodiazepines and related drugs (BZRD) have been equivocal. A recent study reported a 35% excess cancer risk among users of hypnotics, including benzodiazepines.
METHOD: Using Danish nationwide registers, we conducted a matched case-control study of the association between BZRD and cancer risk. During 1 January 2002 and 31 December 2009, we identified 152 510 cases with a first time cancer who were matched (1:8) by age and gender to 1,220,317 cancer-free controls. A new-user design was applied by excluding all subjects who had used anxiolytics, hypnotics or sedatives during the first 2 years of available prescription data (1995-6). Odds ratios (ORs) with 95% confidence intervals (CI) were estimated using conditional logistic regression, adjusting for potential confounders. In the primary analysis, long term use of BZRD was defined by a cumulative amount of ≥500 defined daily doses of BZRD within a period of 1 to 5 years prior to the index date.
RESULTS: The adjusted OR for cancer associated with BZRD use was 1.09 (95% CI 1.04, 1.14). ORs were close to unity for most cancer sites, except stomach 1.40 (95% CI 1.05, 1.88), oesophagus 1.43 (95% CI 1.01, 2.02), liver 1.81 (95% CI 1.18, 2.80), lung 1.38 (95% CI 1.23, 1.54), pancreas 1.35 (95% CI 1.02, 1.79) and kidney 1.39 (95% CI 1.01, 1.91). For tobacco-related cancers, the OR was 1.15 (95% CI 1.09, 1.22) and for the remaining cancer sites 1.01 (95% CI 0.94, 1.08). Sub-group analyses revealed only small differences between different levels of exposure or different patient subgroups.
CONCLUSION: BZRD use was not associated with an overall increase in cancer risk, except for what is likely explained by minor lifestyle confounding, e.g. smoking.
Authors:
Anton Pottegård; Søren Friis; Morten Andersen; Jesper Hallas
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  British journal of clinical pharmacology     Volume:  75     ISSN:  1365-2125     ISO Abbreviation:  Br J Clin Pharmacol     Publication Date:  2013 May 
Date Detail:
Created Date:  2013-04-08     Completed Date:  2013-10-01     Revised Date:  2014-07-31    
Medline Journal Info:
Nlm Unique ID:  7503323     Medline TA:  Br J Clin Pharmacol     Country:  England    
Other Details:
Languages:  eng     Pagination:  1356-64     Citation Subset:  IM    
Copyright Information:
© 2012 The Authors. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Benzodiazepines / adverse effects*
Case-Control Studies
Denmark
Female
Humans
Hypnotics and Sedatives / adverse effects*
Male
Middle Aged
Neoplasms / chemically induced*
Odds Ratio
Registries
Risk Factors
Time Factors
Chemical
Reg. No./Substance:
0/Hypnotics and Sedatives; 12794-10-4/Benzodiazepines
Comments/Corrections
Comment In:
Br J Clin Pharmacol. 2014 Jul;78(1):188-9
Br J Clin Pharmacol. 2014 Jul;78(1):186-7

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Frnakenstein: multiple target inverse RNA folding.
Next Document:  Combining QOF data with the care bundle approach may provide a more meaningful measure of quality in...